Etiology and pathogenesis of Parkinson's disease.
暂无分享,去创建一个
[1] V. Hamburger,et al. A diffusible agent of mouse sarcoma, producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in the chick embryo , 1953 .
[2] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[3] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[4] B. Halliwell,et al. Oxygen radicals and the nervous system , 1985, Trends in Neurosciences.
[5] R. Ramsay,et al. Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.
[6] R. Scheller,et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[7] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[8] C. Marsden,et al. Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.
[9] E. Pileblad,et al. Reduction of Brain Glutathione by l‐Buthionine Sulfoximine Potentiates the Dopamine‐Depleting Action of 6‐Hydroxydopamine in Rat Striatum , 1989, Journal of neurochemistry.
[10] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[11] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[12] J. Langston,et al. Oxidation reactions in Parkinson's disease. Discussion , 1990 .
[13] J. Langston,et al. Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes , 1990, Journal of neurochemistry.
[14] Olanow Cw. Oxidation reactions in Parkinson's disease. , 1990 .
[15] B. Freeman,et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[16] K. Jellinger,et al. Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.
[17] M. Delong,et al. Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.
[18] C. Tanner,et al. Do environmental toxins cause Parkinson's disease? A critical review , 1990, Neurology.
[19] L. Golbe. The genetics of Parkinson's disease: A reconsideration , 1990, Neurology.
[20] C. Olanow. Oxidation reactions in Parkinson's disease , 1990, Neurology.
[21] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[22] S. Snyder,et al. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[23] G. Yancopoulos,et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.
[24] C. W. Olanow,et al. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.
[25] K. Jellinger,et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.
[26] M. Beal,et al. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.
[27] E. Stefani,et al. A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[28] S. Varon,et al. Ciliary neurotrophic factor prevents neuronal degeneration and promotes low affinity NGF receptor expression in the adult rat CNS , 1992, Neuron.
[29] R. North,et al. Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. , 1992, Science.
[30] J S Beckman,et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. , 1992, Archives of biochemistry and biophysics.
[31] S. Varon,et al. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[32] E. Masliah,et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[34] S. Dimauro,et al. Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.
[35] C. Mytilineou,et al. Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.
[36] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[37] C. Olanow. A radical hypothesis for neurodegeneration , 1993, Trends in Neurosciences.
[38] C. Olanow,et al. Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers , 1993, Journal of neuroscience research.
[39] S. Daniel,et al. Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.
[40] C. Marsden,et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.
[41] Mitsutoshi Yamamoto,et al. Differential effects of chronic l-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine , 1994, Neuroscience Letters.
[42] C. Olanow,et al. Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra , 1994, Experimental Neurology.
[43] N. Hattori,et al. An immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's disease , 1994 .
[44] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[45] K. Fuxe,et al. Temporal and spatial increase of astroglial basic fibroblast growth factor synthesis after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine neurons , 1994, Neuroscience.
[46] R. Kurlan,et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease , 1994, Annals of neurology.
[47] F. Watt,et al. Increased Iron in the Substantia Nigra Compacta of the MPTP‐Lesioned Hemiparkinsonian African Green Monkey: Evidence from Proton Microprobe Elemental Microanalysis , 1994, Journal of neurochemistry.
[48] J. Rothstein,et al. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[49] C. Olanow,et al. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study , 1994, Brain Research.
[50] M. Shelanski,et al. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[51] D. Newmeyer,et al. Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria , 1994, Cell.
[52] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[53] D. Holland,et al. (−)‐Deprenyl Reduces PC12 Cell Apoptosis by Inducing New Protein Synthesis , 1994, Journal of neurochemistry.
[54] J. Gusella,et al. Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genes , 1994, Annals of neurology.
[55] J. Hubble,et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease , 1995, Annals of neurology.
[56] J. Connor,et al. A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.
[57] L. Rubin,et al. A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death , 1995, Neuron.
[58] J. Schulz,et al. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity , 1995, Experimental Neurology.
[59] Y. Agid. [Aging, disease and nerve cell death]. , 1995, Bulletin de l'Academie nationale de medecine.
[60] C. Waters,et al. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.
[61] Y Agid,et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[62] Point mutations of mitochondrial genome in Parkinson's disease , 1995 .
[63] David F. Clayton,et al. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.
[64] L. Olson,et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.
[65] Guido Kroemer,et al. The biochemistry of programmed cell death , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[66] J. Schulz,et al. Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.
[67] T. Ozawa,et al. Point mutations of mitochondrial genome in Parkinson's disease. , 1995, Brain research. Molecular brain research.
[68] N. Ip,et al. Time course of ciliary neurotrophic factor mRNA expression is coincident with the presence of protoplasmic astrocytes in traumatized rat striatum , 1995, Journal of neuroscience research.
[69] B J Hoffer,et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys , 1995, The Journal of comparative neurology.
[70] Y. Mizuno,et al. bcl-2 Protein is increased in the brain from parkinsonian patients , 1996, Neuroscience Letters.
[71] M. Beal,et al. Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.
[72] W. Tatton,et al. Reduction of neuronal apoptosis by small molecules: Promise for new approaches to neurological therapy , 1996 .
[73] M. Polymeropoulos,et al. Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.
[74] J. Glowinski,et al. Astrocytes protect neurons from hydrogen peroxide toxicity , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[75] A. Benabid,et al. Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies , 1996, The European journal of neuroscience.
[76] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[77] D. Chuang,et al. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. , 1996, The Journal of pharmacology and experimental therapeutics.
[78] J. Bolaños,et al. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. , 1996, Free radical biology & medicine.
[79] G. Kroemer,et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease , 1996, The Journal of experimental medicine.
[80] Y. Mizuno,et al. Histochemical detection of apoptosis in Parkinson's disease , 1996, Journal of the Neurological Sciences.
[81] G. Davey,et al. Threshold Effects and Control of Oxidative Phosphorylation in Nonsynaptic Rat Brain Mitochondria , 1996, Journal of neurochemistry.
[82] C. Olanow,et al. Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.
[83] Xiaodong Wang,et al. Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.
[84] C. Olanow,et al. Iron and neurodegeneration , 1996 .
[85] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[86] W. Tatton. Modulation of gene expression rather than monoamine oxidase inhibition , 1996, Neurology.
[87] M. Memo,et al. Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-κB Activation , 1996, Science.
[88] P. Lansbury,et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.
[89] Annette M. Schmid,et al. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones , 1996, Neuroreport.
[90] K. Davis,et al. A pilot study of prednisone in Alzheimer's disease. , 1996, Dementia.
[91] S. Sakoda,et al. Pentoxifylline delays the onset of experimental allergic encephalomyelitis in mice by modulating cytokine production in peripheral blood mononuclear cells. , 1996, Immunopharmacology.
[92] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[93] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[94] C. Olanow,et al. l‐(−)‐Desmethylselegiline, a Metabolite of Selegiline [l‐(−)‐Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In Vitro , 1997, Journal of neurochemistry.
[95] S. Kish,et al. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.
[96] J. H. Li,et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[97] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[98] K. Castagnoli,et al. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1997, Chemical research in toxicology.
[99] S. Jiao,et al. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery , 1997, Neuroscience.
[100] C. Marsden,et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease , 1997, The Lancet.
[101] C D Marsden,et al. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.
[102] Y Agid,et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[103] Y. Agid,et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.
[104] W. Tatton,et al. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. , 1997, Journal of neural transmission. Supplementum.
[105] C. Olanow,et al. l‐Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor‐Mediated Toxicity In Vitro , 1997, Journal of neurochemistry.
[106] A. Lees,et al. A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.
[107] S. Snyder,et al. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[108] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[109] M. Polymeropoulos. Autosomal dominant parkinson's disease and α‐synuclein , 1998 .
[110] L. Scorrano,et al. The mitochondrial permeability transition , 2022, BioFactors.
[111] J. Obeso,et al. Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.
[112] Genetic risk factors in parkinson's disease , 1998, Annals of neurology.
[113] W. Tatton,et al. Mitochondrial Membrane Potential and Nuclear Changes in Apoptosis Caused by Serum and Nerve Growth Factor Withdrawal: Time Course and Modification by (؊)-deprenyl , 2022 .
[114] D. Perl,et al. A fluorescent double‐labeling method to detect and confirm apoptotic nuclei in parkinson's disease , 1998, Annals of neurology.
[115] P. Jenner,et al. Understanding cell death in parkinson's disease , 1998, Annals of neurology.
[116] P. Damier,et al. Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.
[117] Olaf Riess,et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.
[118] C. Olanow,et al. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. , 1998, The Journal of pharmacology and experimental therapeutics.
[119] D. Perl,et al. Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.
[120] Zhiming Zhang,et al. Neuroprotective and neurorestorative properties of GDNF , 1998, Annals of neurology.
[121] T. Jessell,et al. The specification of dorsal cell fates in the vertebrate central nervous system. , 1999, Annual review of neuroscience.
[122] B. Wandell. Computational neuroimaging of human visual cortex. , 1999, Annual review of neuroscience.
[123] P. Mombaerts,et al. Molecular biology of odorant receptors in vertebrates. , 1999, Annual review of neuroscience.
[124] L. Rubin,et al. The cell biology of the blood-brain barrier. , 1999, Annual review of neuroscience.
[125] B. Mueller,et al. Growth cone guidance: first steps towards a deeper understanding. , 1999, Annual review of neuroscience.
[126] J. Schall,et al. Neural selection and control of visually guided eye movements. , 1999, Annual review of neuroscience.
[127] G. Baltuch,et al. Microglia as mediators of inflammatory and degenerative diseases. , 1999, Annual review of neuroscience.
[128] S. Landis,et al. Cellular and molecular determinants of sympathetic neuron development. , 1999, Annual review of neuroscience.
[129] W. Betz,et al. Monitoring secretory membrane with FM1-43 fluorescence. , 1999, Annual review of neuroscience.